Clinical Trial Update: Open Label Extension Study to Evaluate the Safety and Tolerability of Oral Fampridine-Sustained Release (SR) in Canadian Participants With Multiple Sclerosis Who Participated in Acorda Extension Trials. [Phase 3]

View source ↗

Summary

This is an open-label extension study in Canadian participants with multiple sclerosis evaluating safety and tolerability of oral dalfampridine sustained-releas…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Ampyra (dalfampridine) SR (dalfampridine sustained-release)

Snippet

Sponsor: Biogen | Conditions: Multiple Sclerosis | Phase 3 | Status: COMPLETED